Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.51 |
| ▸ | CA2 | P00918 | 13/20 | 0.51 |
| ▸ | CA9 | Q16790 | 13/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | F11 | P03951 | 3/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443260 | 0.88 | CA1 (0.49) | CA1CA2CA9CA12CA3 | |
| SCHEMBL446061 | 0.85 | ALDH1A1 (0.51) | CA1CA2CA9CA12CA3 | |
| SCHEMBL118986 | 0.85 | CA1 (0.51) | CA1CA2CA9CA12CA3 | |
| SCHEMBL2380393 | 0.82 | CA1 (0.49) | CA1CA2CA9CA12CA3 | |
| SCHEMBL443866 | 0.82 | MEN1 (0.52) | CA1CA2CA9CA12CA3 | |
| SCHEMBL440627 | 0.81 | CNR1 (0.57) | CA1CA2CA9CA12CA3 | |
| SCHEMBL3732362 | 0.81 | CA1 (0.48) | CA1CA2CA9CA12CA3 | |
| SCHEMBL444777 | 0.81 | CA1 (0.48) | CA1CA2CA9CA12CA3 | |
| SCHEMBL251814 | 0.81 | CA1 (0.59) | CA1CA2CA9CA12CA3 | |
| SCHEMBL15567289 | 0.80 | L3MBTL1 (0.48) | CA1CA2CA9CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406258-B1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LTD (GB) | 2014-12-03 | — | — | EP | disclosed |
| EP-2406258-B1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LTD (GB) | 2014-12-03 | — | — | EP | disclosed |
| US-20140296234-A1 | PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED | 2014-10-02 | — | — | US | disclosed |
| US-20140296234-A1 | PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED | 2014-10-02 | — | — | US | disclosed |
| US-8785457-B2 | Pyrimidine derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2014-07-22 | — | — | US | disclosed |
| US-8785457-B2 | Pyrimidine derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2014-07-22 | — | — | US | disclosed |
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| EP-2406258-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | Cellzome Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103094-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103094-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | CA1 4867/4885CA2 4488/4885CA9 4749/4885 |
| US-20140296234-A1 | PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | CA1 4867/4885CA2 4488/4885CA9 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.